2026-09-28T20:40:23.000Z · 5 days ago Lite Strategy files to sell 1.89M shares of common stock for holders
Sep 10, 2026, 9:00 AM EDT · 23 days ago Lite Strategy to Present at the 28th Annual H.C. Wainwright Global Investment Conference in New York
Jul 30, 2026, 8:30 AM EDT · 2 months ago Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share
Jun 19, 2026, 8:30 AM EDT · 3 months ago Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam LTC
2026-02-17T14:00:57.000Z · 7 months ago Lite Strategy to continue to evaluate strategic investments in 2H of 2026
2025-11-19T16:15:44.000Z · 10 months ago Lite Strategy names acting CEO Justin File to role on a permanent basis
2025-11-17T14:05:45.000Z · 10 months ago Lite Strategy reports Q1 results, highlights launch of $100M Litecoin Treasury
2025-10-08T20:50:10.000Z · 12 months ago Lite Strategy files to sell 780,497 shares of common stock for holders
Sep 10, 2025, 9:00 AM EDT · 1 year ago MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'
Aug 5, 2025, 8:00 AM EDT · 1 year ago MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising
Jul 24, 2025, 8:00 PM EDT · 1 year ago BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode
Jul 22, 2025, 4:35 PM EDT · 1 year ago MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
Jul 18, 2025, 8:30 AM EDT · 1 year ago MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
May 13, 2025, 4:05 PM EDT · 1 year ago MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
Feb 12, 2025, 4:12 PM EST · 1 year ago MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
Nov 12, 2024, 4:05 PM EST · 1 year ago MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
Aug 12, 2024, 8:30 AM EDT · 2 years ago MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
May 9, 2024, 4:02 PM EDT · 2 years ago MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
Apr 11, 2024, 8:02 AM EDT · 2 years ago MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
Apr 11, 2024, 8:00 AM EDT · 2 years ago MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
Apr 10, 2024, 8:00 AM EDT · 2 years ago MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Mar 26, 2024, 8:00 AM EDT · 2 years ago MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Feb 13, 2024, 5:05 PM EST · 2 years ago MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
Jan 16, 2024, 5:00 PM EST · 2 years ago MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
Dec 11, 2023, 12:00 PM EST · 2 years ago MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
Nov 9, 2023, 4:05 PM EST · 2 years ago MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights
Nov 8, 2023, 8:00 AM EST · 2 years ago MEI Pharma to Present at the Stifel 2023 Healthcare Conference
Nov 6, 2023, 4:57 PM EST · 2 years ago MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
Nov 2, 2023, 9:00 AM EDT · 2 years ago MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023
Nov 1, 2023, 9:00 AM EDT · 2 years ago MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital
Sep 28, 2023, 5:00 PM EDT · 3 years ago MEI Pharma Issues Statement Regarding Anson and Cable Car's Opportunistic Actions
Sep 26, 2023, 4:02 PM EDT · 3 years ago MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights
Sep 21, 2023, 8:00 AM EDT · 3 years ago MEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023
Sep 18, 2023, 8:00 AM EDT · 3 years ago MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car
Aug 16, 2023, 8:00 AM EDT · 3 years ago MEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal Cancer
Jul 23, 2023, 2:30 PM EDT · 3 years ago MEI Pharma Announces Results of Special Meeting of Stockholders
Jul 19, 2023, 8:00 AM EDT · 3 years ago MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
Jul 17, 2023, 8:00 AM EDT · 3 years ago MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
Jul 11, 2023, 8:00 AM EDT · 3 years ago MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals
Jul 7, 2023, 8:00 AM EDT · 3 years ago MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals
Jul 5, 2023, 8:30 AM EDT · 3 years ago ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.
Jul 5, 2023, 8:00 AM EDT · 3 years ago MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals
Jun 29, 2023, 8:00 AM EDT · 3 years ago MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
Jun 15, 2023, 12:08 PM EDT · 3 years ago MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
